KMR Group Release: Evaluate CRO Performance With CRO Metrix
CHICAGO, Illinois, May 12, 2016 – KMR Group, a leader in biopharmaceutical R&D performance analytics, announces their newest online clinical trial performance application, CRO Metrix, is now live. The tool helps clinical research organizations and sponsor biopharmaceutical companies assess the performance of CROs.
Addressing outsourcing performance is increasingly necessary as more clinical trial components are being outsourced. Both sponsor companies and CROs need to know performance expectations, which helps to plan trial timelines and accuracy in proposals. While certain differences in outsourced work compared to internal are to be expected, having a foundation in proven performance has been difficult to acquire.
CRO Metrix, the new application from KMR Group, uses a foundation of thousands of recent trials both insourced and outsourced to provide clients with realistic timelines for clinical trial processes and related metrics. The tool answers common outsourcing related questions e.g. what timelines are realistic for certain processes, including key performance drivers such as study startup or report writing, by phase and disease among other criteria.
Besides answering specific questions that may be of interest to trial planners, the tool also addresses what is on many minds in the Industry - how does performance differ across sponsor vs. CRO conducted trials? As clinical trial complexity increases and geographic scope is broadened, the type of information available in CRO Metrix may just help both sponsors and CROs improve overall trial performance to help facilitate moving critical new therapies to market faster.
“Utilizing recent outsourced and internal trials, along with KMR Group’s proven methodology the possibilities for employing CRO Metrix are quite impressive,” commented Scott Martin, Principal at KMR Group. “Anyone involved with Outsourced trial planning would find viewing their performance and Industry performance highly invaluable.”
CRO Metrix complements the company’s current Outsourcing Performance Study. Companies interested in licensing the application are encouraged to contact KMR Group.
For more information about KMR’s CRO Metrix application contact: Lyndsey McKay, Marketing and Communications Manager Tel: +1 (312) 795-0400 Email: lmckay [at] kmrgroup.com
About KMR
KMR Group has worked exclusively in biopharmaceutical R&D since the early 1990s. KMR Group is an industry leader in benchmarking, analytics and performance management as well as a developer of on-line analytics tools that enable access to our propriety and rich datasets. KMR's clinical platform contains the most reliable source for trial performance, recruitment and site metrics data, with over 25,000 global clinical trials. Clients depend on these tools to benchmark performance, define recruitment strategies and shape enrollment plans and to identify best performing sites. For more information or for a demonstration of any of KMR's tools, please contact us.
Addressing outsourcing performance is increasingly necessary as more clinical trial components are being outsourced. Both sponsor companies and CROs need to know performance expectations, which helps to plan trial timelines and accuracy in proposals. While certain differences in outsourced work compared to internal are to be expected, having a foundation in proven performance has been difficult to acquire.
CRO Metrix, the new application from KMR Group, uses a foundation of thousands of recent trials both insourced and outsourced to provide clients with realistic timelines for clinical trial processes and related metrics. The tool answers common outsourcing related questions e.g. what timelines are realistic for certain processes, including key performance drivers such as study startup or report writing, by phase and disease among other criteria.
Besides answering specific questions that may be of interest to trial planners, the tool also addresses what is on many minds in the Industry - how does performance differ across sponsor vs. CRO conducted trials? As clinical trial complexity increases and geographic scope is broadened, the type of information available in CRO Metrix may just help both sponsors and CROs improve overall trial performance to help facilitate moving critical new therapies to market faster.
“Utilizing recent outsourced and internal trials, along with KMR Group’s proven methodology the possibilities for employing CRO Metrix are quite impressive,” commented Scott Martin, Principal at KMR Group. “Anyone involved with Outsourced trial planning would find viewing their performance and Industry performance highly invaluable.”
CRO Metrix complements the company’s current Outsourcing Performance Study. Companies interested in licensing the application are encouraged to contact KMR Group.
For more information about KMR’s CRO Metrix application contact: Lyndsey McKay, Marketing and Communications Manager Tel: +1 (312) 795-0400 Email: lmckay [at] kmrgroup.com
About KMR
KMR Group has worked exclusively in biopharmaceutical R&D since the early 1990s. KMR Group is an industry leader in benchmarking, analytics and performance management as well as a developer of on-line analytics tools that enable access to our propriety and rich datasets. KMR's clinical platform contains the most reliable source for trial performance, recruitment and site metrics data, with over 25,000 global clinical trials. Clients depend on these tools to benchmark performance, define recruitment strategies and shape enrollment plans and to identify best performing sites. For more information or for a demonstration of any of KMR's tools, please contact us.